Ondansetron used to be the preserve of the Oncologists for children struggling with chemotherapy-induced nausea. Recently, however, its use for the symptomatic relief of nausea and vomiting in the Emergency Department has significantly increased.
Less vomiting = less chance of dehydration and need for admission for fluids. All good? Well, not quite.
In 2011 in the USA the Food and Drug Administration (FDA) issued a warning that Ondansetron administration was associated with fatal arrhythmias. So, should we stop using ondansetron? What’s the actual risk of arrhythmia?